Sheet 1 of 2

		<u>J</u>											
FORM PTE		1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.:				APPLICATION NO.:			
RADEN	ARK				OC01617K1	10/776, 988							
Paues	INF	ORM	IATION DISCLOS	APPLICANT:									
			BY APPLIC	Timothy J. Guzi et al.									
1		// /		:		FILING DATE:			GROUP; , "				
		(U	se several sheets	ıı necessary	nococcana 1		02/11/2004		GROUP L'U				
· U.S. PATENT DOCUMENTS													
	*EXAMINER DOCUMENT DATE NAME (CL	ASS	SU		FILING I		
INIT			NUMBER							SS	APPROPRIATE		
	V	AA	5,571,813	11/05/1996		r et al.	┞	-	Ļ	<u> </u>	ļ		
	4	AB	5,602,136	02/11/1997		r et al.	<u> </u>	+-	igsquare				
	4	AC	5,602,137	02/11/1997		r et al.	_	↓	\sqcup				
<u> </u>	-	AD	5,688,949	11/18/1997		et al.	<u> </u>	 			ļ		
		AE	5,707,997	01/13/1998		et al.	<u> </u>	<u> </u>	\sqcup				
		AF	5,919,815	07/06/1999		y et al.		<u> </u>	Ш	<u> </u>			
	4_	AG	6,040,321	03/21/2000		et al.	ļ	<u> </u>	\sqcup				
<u> </u>		AH	6,107,305	08/22/2000		et al.	↓		\sqcup				
ļ	1_	Al	6,191,131	02/20/2001		et al.			igsquare				
	\mathbb{Z}	AJ	6,262,096	07/17/2001		et al.			ш				
L	<u> </u>	AK	6,413,974	07/02/2002	Dumoi	nt <i>et al.</i>			Щ		L		
			F	OREIGN P	ATENT DOC	UMENTS	,	ı	•				
			DOCUMENT	DATE	COUNTRY		CL	ASS	SUB	J -	TRANSI	NOITA	
			NUMBER						CLA	SS	YES	NO	
4	7	AL	DE 102 23 917 A1	11/12/2003	Gerr	nany							
	T	AM	EP 0 628 559	04/03/2002		оре	 						
		AN	EP 1 334 973	08/13/2003	Eur	оре							
		AO	WO 02/22610	03/21/2002		CT							
		AP	WO 02/40485	05/23/2002	P	CT							
		AQ	WO 02/50079	06/27/2002	· P(CT ·							
	1/	AR	WO 03/091256 A1	11/06/2003	P	CT							
	V	AS	WO 95/35298	12/28/1995	P	T							
		OTI	HER DOCUMENT	S (Including	Author Title	. Date Perti	iner	nt Pa	ides	Ft	c)	•	
			Vesely et al., "Inhibit									$\overline{}$	
l Y	/	' '	(1994), 224: 771-786		opondom runci	, oo by t dio / .		guou	,		D.00		
1		ΑŪ	Kim et al., "Discover		zole Inhibitors o	f Cyclin-Depen	den	t Kina	se 2:	Svn	thesis.	X-rav	
1 1			Crystallographic Ana	lysis, and Biol	ogical Activities	". Journal of Me	dica	al Che	əmist	rv. (2	2002). 4	5:	
	•		3905-3927.		•	•				<i>y</i> , (-	/,		
		ΑV	Mettey et al., "Aloisir	nes, a New Far	nily of CDK/GS	K-3 Inhibitors.	SAF	₹ Stud	Jy, Ci	rysta	Structu	ire in	
j (Complex with CDK2										
			236.										
1		AW Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-											
	a]pyrimidines", J. Med. Chem. (1977), 20(2): 296-299.												
		AX Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent											
	Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (September									ember			
	1998), 16(9): 2986-2999.												
U	AY Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of									or of			
-		<u>L</u>	the Cyclin-Depender	Kinases CDC	C2, CDK2 and (CDK5", <i>Eur. J. I</i>	Bioc	hem.	<u>(199</u>	7), 2	43:527-	536.	
EXAMINER DATE CONSIDERED													
Om 14 chr. 6/17/67													
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line													
-through	h cita	is. III Ation i	f not in conformatice	and not consid	i oi noi citation lered Include	no jii comoniyar	n wi	wiiii IV th nev	iii Er	טטט יישמ	nication	to	
applic			. Hot in comormatice	and not consid	icico. illolude (Jopy or una ion	**!	/16/		·	moanon	.	
	аррікані.												

FORM PTO	D-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01617K1	APPLICATION NO.: 10/776,988							
INF	ORM	IATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Timothy J. Guzi et al.								
	(U	se several sheets if necessary)	FILING DATE: 02/22/2004	GROUP:							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	AZ Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (Augus 15, 1997), 57: 3375-3380.										
	ВА	A Shiota <i>et al.</i> , "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47 (7): 928-938.									
	BB	BB Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)									
	ВС										
	BD										
	BE										
	BF Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage", Journal of Cell Science (1995), 108: 2897-2904.										
	BG										
10	ВН	Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-triazines ¹ ", Journal of Medicinal Chemistry, (1976), 19(4): 517-520.									
	BI		1								
DATE CONSIDERED 6/7/67											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											